Aurinia Pharmaceuticals Inc (AUPH) FY2025Q4 Earning Prediction
Aurinia Pharmaceuticals Inc (AUPH) is set to release its earnings performance on 02/25 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 74.00M and an earnings per share (EPS) of 0.21 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
AUPH Transcript
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
The earnings call presents a strong financial performance with a 24% revenue increase and a transition to net income, alongside a robust gross margin. The share repurchase program indicates confidence in the stock. Despite potential challenges like supply chain issues and patent litigation, the optimistic guidance and strategic focus on growth drivers are positive. The Q&A highlights management's proactive approach to market dynamics, suggesting stability and potential growth. Given these factors, the stock is likely to see a positive movement, with a potential increase of 2% to 8% over the next two weeks.
The earnings call indicates strong financial performance with a 24% revenue increase and a shift to net income. The share repurchase program also suggests confidence in stock value. Despite potential supply chain challenges and patent litigation, management's optimism on market expansion and operational efficiency is reassuring. The Q&A revealed positive sentiment towards sales guidance and market growth, with minimal impact from tariffs. Overall, the positive financial metrics, share repurchase, and optimistic guidance outweigh potential risks, suggesting a positive stock price movement.
AUPH Report
Frequently Asked Questions
What is the Aurinia Pharmaceuticals Inc FY2025Q4 Earnings Release Date and Time?
Aurinia Pharmaceuticals Inc (AUPH) is scheduled to release its FY2025Q4 earnings report onFeb 25, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Aurinia Pharmaceuticals Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 74.00M in revenue and an EPS of 0.00 for Aurinia Pharmaceuticals Inc's FY2025Q4.
What Does Intellectia's AI Predict for Aurinia Pharmaceuticals Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a forAurinia Pharmaceuticals Inc's FY2025Q4 earnings, with a prediction date of Feb 25, 2026. Aurinia Pharmaceuticals Inc
How Can I Use This Earnings Prediction to Trade AUPH Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 25, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Aurinia Pharmaceuticals Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
